Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (NYSE: FLAG) is a clinical-stage oncology company that went public through a de-SPAC merger with First Light Acquisition Group, a blank check company sponsored by First Light Acquisition Group's management team that completed its IPO in 2021. The business combination closed in 2023, listing Calidi's engineered stem cell platform for oncolytic virus-based cancer immunotherapy under the FLAG ticker. The company filed an 8-K current report with the SEC on May 14, 2026, representing the latest entry in its post-merger public disclosure record. Calidi operates in the biotechnology and oncology sector. Sign up on SpacDesk to access the full filing history, SPAC deal timeline, and real-time alerts for FLAG and hundreds of other de-SPAC companies.